TY - JOUR
T1 - Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity
AU - Ding, Chunyong
AU - Wang, Fengyang
AU - Dang, Yijing
AU - Xu, Zhiai
AU - Li, Lingling
AU - Lai, Yi
AU - Yu, Haijun
AU - Luo, Yi
AU - Huang, Ruimin
AU - Zhang, Ao
AU - Zhang, Wen
N1 - Publisher Copyright:
Copyright © 2019 American Chemical Society.
PY - 2019/12/17
Y1 - 2019/12/17
N2 - The accurate detection of tumorous methylglyoxal (MGO) and its detoxifier glyoxalase 1 (GLO1) in living systems is critical for understanding their roles in tumor initiation and progression. To date, the in situ fluorescence detection of endogenous MGO and GLO1 in tumor has not been reported. Herein we developed a near-infrared (NIR) fluorescent probe MEBTD to specifically detect tumorous MGO. Compared with previously reported MGO fluorescent probes, MEBTD exhibits several distinct advantages, including NIR emission, high selectivity with an MGO detection limit of 18 nM, and a 131-fold off-on ratio. The probe could sense GLO1 activity and monitor the therapeutic effect of GLO1 inhibitors by imaging tumorous MGO in a both a real-time and in situ manner, demonstrating that the biological effect of GLO1 inhibitors is dependent on the GLO1 activity. Furthermore, MEBTD enables the visualization of tumorous MGO induced by GLO1 inhibitors in vivo. To the best of our knowledge, MEBTD is the first NIR fluorescent probe for specifically imaging tumorous MGO in living animals, indicating the promising potential for tumor diagnosis and therapeutic evaluation.
AB - The accurate detection of tumorous methylglyoxal (MGO) and its detoxifier glyoxalase 1 (GLO1) in living systems is critical for understanding their roles in tumor initiation and progression. To date, the in situ fluorescence detection of endogenous MGO and GLO1 in tumor has not been reported. Herein we developed a near-infrared (NIR) fluorescent probe MEBTD to specifically detect tumorous MGO. Compared with previously reported MGO fluorescent probes, MEBTD exhibits several distinct advantages, including NIR emission, high selectivity with an MGO detection limit of 18 nM, and a 131-fold off-on ratio. The probe could sense GLO1 activity and monitor the therapeutic effect of GLO1 inhibitors by imaging tumorous MGO in a both a real-time and in situ manner, demonstrating that the biological effect of GLO1 inhibitors is dependent on the GLO1 activity. Furthermore, MEBTD enables the visualization of tumorous MGO induced by GLO1 inhibitors in vivo. To the best of our knowledge, MEBTD is the first NIR fluorescent probe for specifically imaging tumorous MGO in living animals, indicating the promising potential for tumor diagnosis and therapeutic evaluation.
UR - https://www.scopus.com/pages/publications/85076321480
U2 - 10.1021/acs.analchem.9b03600
DO - 10.1021/acs.analchem.9b03600
M3 - 文章
C2 - 31794195
AN - SCOPUS:85076321480
SN - 0003-2700
VL - 91
SP - 15577
EP - 15584
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 24
ER -